Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 1567 drug-target rows in SSL view, for TSG = PTPRD.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
docetaxel, thalidomide PTPRD TUBB1 4
docetaxel, thalidomide PTPRD MAPT 4
docetaxel, thalidomide PTPRD MAP4 4
docetaxel, thalidomide PTPRD BCL2 4
docetaxel, thalidomide PTPRD MAP2 4
docetaxel, thalidomide PTPRD NR1I2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PTPRD TUBB1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PTPRD MAPT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PTPRD MAP4 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PTPRD BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PTPRD MAP2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PTPRD NR1I2 4
amg 193, docetaxel, comparator amg 193 test tablet PTPRD TUBB1 3
amg 193, docetaxel, comparator amg 193 test tablet PTPRD MAPT 3
amg 193, docetaxel, comparator amg 193 test tablet PTPRD MAP4 3
amg 193, docetaxel, comparator amg 193 test tablet PTPRD BCL2 3
amg 193, docetaxel, comparator amg 193 test tablet PTPRD MAP2 3
amg 193, docetaxel, comparator amg 193 test tablet PTPRD NR1I2 3
bms-986340, bms-936558-01, docetaxel PTPRD TUBB1 3
bms-986340, bms-936558-01, docetaxel PTPRD MAPT 3
bms-986340, bms-936558-01, docetaxel PTPRD MAP4 3
bms-986340, bms-936558-01, docetaxel PTPRD BCL2 3
bms-986340, bms-936558-01, docetaxel PTPRD MAP2 3
bms-986340, bms-936558-01, docetaxel PTPRD NR1I2 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PTPRD TUBB1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PTPRD MAPT 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PTPRD MAP4 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PTPRD BCL2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PTPRD MAP2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PTPRD NR1I2 2
alvocidib, paclitaxel PTPRD TUBB1 2
alvocidib, paclitaxel PTPRD MAPT 2
alvocidib, paclitaxel PTPRD MAP4 2
alvocidib, paclitaxel PTPRD BCL2 2
alvocidib, paclitaxel PTPRD MAP2 2
alvocidib, paclitaxel PTPRD NR1I2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PTPRD TUBB1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PTPRD MAPT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PTPRD MAP4 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PTPRD BCL2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PTPRD MAP2 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PTPRD NR1I2 2
bbi-355, erlotinib, futibatinib PTPRD NR1I2 2
biopsy, biospecimen collection, computed tomography, cyclophosphamide, fludarabine phosphate, fludeoxyglucose f-18, il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells, magnetic resonance imaging, positron emission tomography PTPRD NR1I2 2
bpi-7711, bpi-7711, itraconazole, rifampicin PTPRD NR1I2 2
bryostatin 1, paclitaxel PTPRD TUBB1 2
bryostatin 1, paclitaxel PTPRD MAPT 2
bryostatin 1, paclitaxel PTPRD MAP4 2
bryostatin 1, paclitaxel PTPRD BCL2 2
bryostatin 1, paclitaxel PTPRD MAP2 2
bryostatin 1, paclitaxel PTPRD NR1I2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin PTPRD TUBB1 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin PTPRD MAPT 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin PTPRD MAP4 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin PTPRD BCL2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin PTPRD MAP2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin PTPRD NR1I2 2
cabazitaxel PTPRD TUBB1 2
capecitabine, docetaxel PTPRD TUBB1 2
capecitabine, docetaxel PTPRD MAPT 2
capecitabine, docetaxel PTPRD MAP4 2
capecitabine, docetaxel PTPRD BCL2 2
capecitabine, docetaxel PTPRD MAP2 2
capecitabine, docetaxel PTPRD NR1I2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PTPRD TUBB1 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PTPRD MAPT 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PTPRD MAP4 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PTPRD BCL2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PTPRD MAP2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PTPRD NR1I2 2
carboplatin, docetaxel PTPRD TUBB1 2
carboplatin, docetaxel PTPRD MAPT 2
carboplatin, docetaxel PTPRD MAP4 2
carboplatin, docetaxel PTPRD BCL2 2
carboplatin, docetaxel PTPRD MAP2 2
carboplatin, docetaxel PTPRD NR1I2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection PTPRD TUBB1 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection PTPRD MAPT 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection PTPRD MAP4 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection PTPRD BCL2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection PTPRD MAP2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection PTPRD NR1I2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu PTPRD TUBB1 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu PTPRD MAPT 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu PTPRD MAP4 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu PTPRD BCL2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu PTPRD MAP2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu PTPRD NR1I2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD TUBB1 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD MAPT 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD MAP4 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD BCL2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD MAP2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD NR1I2 2
carboplatin, paclitaxel, panitumumab, radiotherapy PTPRD TUBB1 2
carboplatin, paclitaxel, panitumumab, radiotherapy PTPRD MAPT 2
carboplatin, paclitaxel, panitumumab, radiotherapy PTPRD MAP4 2
carboplatin, paclitaxel, panitumumab, radiotherapy PTPRD BCL2 2
carboplatin, paclitaxel, panitumumab, radiotherapy PTPRD MAP2 2
carboplatin, paclitaxel, panitumumab, radiotherapy PTPRD NR1I2 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 PTPRD TUBB1 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 PTPRD MAPT 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 PTPRD MAP4 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 PTPRD BCL2 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 PTPRD MAP2 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 PTPRD NR1I2 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy PTPRD TUBB1 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy PTPRD MAPT 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy PTPRD MAP4 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy PTPRD BCL2 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy PTPRD MAP2 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy PTPRD NR1I2 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy PTPRD TUBB1 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy PTPRD MAPT 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy PTPRD MAP4 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy PTPRD BCL2 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy PTPRD MAP2 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy PTPRD NR1I2 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy PTPRD TUBB1 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy PTPRD MAPT 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy PTPRD MAP4 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy PTPRD BCL2 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy PTPRD MAP2 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy PTPRD NR1I2 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy PTPRD TUBB1 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy PTPRD MAPT 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy PTPRD MAP4 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy PTPRD BCL2 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy PTPRD MAP2 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy PTPRD NR1I2 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PTPRD TUBB1 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PTPRD MAPT 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PTPRD MAP4 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PTPRD BCL2 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PTPRD MAP2 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy PTPRD NR1I2 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PTPRD TUBB1 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PTPRD MAPT 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PTPRD MAP4 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PTPRD BCL2 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PTPRD MAP2 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy PTPRD NR1I2 2
cisplatin, paclitaxel, surgical procedure, radiation therapy PTPRD TUBB1 2
cisplatin, paclitaxel, surgical procedure, radiation therapy PTPRD MAPT 2
cisplatin, paclitaxel, surgical procedure, radiation therapy PTPRD MAP4 2
cisplatin, paclitaxel, surgical procedure, radiation therapy PTPRD BCL2 2
cisplatin, paclitaxel, surgical procedure, radiation therapy PTPRD MAP2 2
cisplatin, paclitaxel, surgical procedure, radiation therapy PTPRD NR1I2 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study PTPRD TUBB1 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study PTPRD MAPT 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study PTPRD MAP4 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study PTPRD BCL2 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study PTPRD MAP2 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study PTPRD NR1I2 2
cyclophosphamide, neoantigen peptide vaccine, pembrolizumab, sargramostim PTPRD NR1I2 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg PTPRD TUBB1 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg PTPRD MAPT 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg PTPRD MAP4 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg PTPRD BCL2 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg PTPRD MAP2 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg PTPRD NR1I2 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone PTPRD TUBB1 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone PTPRD MAPT 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone PTPRD MAP4 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone PTPRD BCL2 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone PTPRD MAP2 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone PTPRD NR1I2 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PTPRD TUBB1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PTPRD MAPT 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PTPRD MAP4 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PTPRD BCL2 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PTPRD MAP2 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PTPRD NR1I2 2
erlotinib PTPRD NR1I2 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PTPRD TUBB1 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PTPRD MAPT 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PTPRD MAP4 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PTPRD BCL2 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PTPRD MAP2 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy PTPRD NR1I2 2
filgrastim, paclitaxel, topotecan hydrochloride PTPRD TUBB1 2
filgrastim, paclitaxel, topotecan hydrochloride PTPRD MAPT 2
filgrastim, paclitaxel, topotecan hydrochloride PTPRD MAP4 2
filgrastim, paclitaxel, topotecan hydrochloride PTPRD BCL2 2
filgrastim, paclitaxel, topotecan hydrochloride PTPRD MAP2 2
filgrastim, paclitaxel, topotecan hydrochloride PTPRD NR1I2 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD TUBB1 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD MAPT 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD MAP4 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD BCL2 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD MAP2 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy PTPRD NR1I2 2
gefitinib, fulvestrant, erlotinib PTPRD NR1I2 2
gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy PTPRD TUBB1 2
gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy PTPRD MAPT 2
gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy PTPRD MAP4 2
gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy PTPRD BCL2 2
gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy PTPRD MAP2 2
gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy PTPRD NR1I2 2
hlx208, hlx208, hlx208, hlx208, itraconazole 200 mg, rifampicin PTPRD NR1I2 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.